Avecris

Executive Summary

Avecris is a Singapore-based biotechnology company developing SPRING DNA, a non-viral programmable DNA delivery platform designed to enable sustained, cell-type-specific expression of therapeutic proteins. The platform offers potential advantages over viral vectors, including scalable and low-cost manufacturing, and is applicable across a wide range of therapeutic areas such as genetic diseases, metabolic disorders, oncology, and immunology. Founded in 2020, the company is currently in preclinical stage and has raised $60 million to advance its platform toward clinical validation. The versatility of SPRING DNA positions it as a potential next-generation gene therapy platform that could overcome key limitations of viral-based approaches, including immunogenicity and manufacturing complexity. While the company has not disclosed specific preclinical data, its broad therapeutic focus and significant early-stage funding suggest strong investor confidence. Key risks include the early stage of development, lack of clinical proof-of-concept, and the inherent challenges of non-viral in vivo delivery. However, if successful, SPRING DNA could have a transformative impact across multiple disease areas. Upcoming catalysts include potential IND filings, strategic partnerships, and presentations of preclinical data at major conferences. Overall, Avecris represents a compelling but high-risk opportunity in the gene therapy landscape.

Upcoming Catalysts (preview)

• H1 2027IND filing for lead program20% success
• 2026Strategic partnership or licensing deal30% success
• H2 2026Presentation of preclinical data at a major conference50% success